Skip to content
Screener

Hemab Therapeutics Holdings, Inc. COAG Preferred Share Shares Authorized

Preferred Share Shares Authorized at other companies

ESN
Essent GroupESNT
$500M
ESN
Essent GroupESNT
$500M
BK
BKBK
100M0.0%
The Travelers Companies logo
The Travelers CompaniesTRV
5M0.0%
General Dynamics logo
General DynamicsGD
50M0.0%
Rockwell Automation logo
Rockwell AutomationROK
25M0.0%

Other financials

Income statement

See full
Operating income-$26.1M-62.4%
Net income-$24.2M-97.8%
EPS (diluted)-$0.80+93.8%

Balance sheet

See full
Cash & equivalents$237.4M
Total debt$1.0M
Total equity$454.3M+421%
Total assets$467.8M

Cash flow

See full
Operating cash flow-$22.6M-47.6%
CapEx$23.0K
Free cash flow-$22.7M-47.8%

Valuation

See full
Market cap$2.32B+107%
Enterprise value$2.08B

Returns & leverage

See full
Return on equity-45.7%
Debt / equity
Current ratio35.8×

Where this comes from

Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.

Tagged under the XBRL concept coag:PreferredShareSharesAuthorized.

The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344533
Line itemJune 30, 2026December 31, 2025
Stockholders’ deficit:
Ordinary shares, DKK 1 par value; no shares and 946,000 shares authorized, issued, and outstanding as of June 30, 2026 and December 31, 2025, respectively132
Common stock, $0.0001 par value; 400,000,000 shares and no shares authorized as of June 30, 2026 and December 31, 2025, respectively; 46,705,410 shares and no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively5
Preferred stock, $0.0001 par value; 5,000,000 shares and no shares authorized as of June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Additional paid-in capital685,7094,916
Accumulated deficit(228,695)(181,858)
Accumulated other comprehensive (loss) income(2,748)175
Total stockholders’ equity (deficit)454,271(176,635)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Hemab Therapeutics Holdings, Inc.'s preferred share shares authorized?
Hemab Therapeutics Holdings, Inc. (COAG) reported preferred share shares authorized of $0 in Q4 2025.
What does preferred share shares authorized mean?
Preferred Share Shares Authorized as reported by Hemab Therapeutics Holdings, Inc. Common Stock.

Ask your AI about Hemab Therapeutics Holdings, Inc.'s preferred share shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude